Skip to content Skip to footer
Subscribe Now

NEWS

Life Spine Receives US FDA’s 510(k) Clearance for ProLift Pivot Expandable Spacer System
Shots: The US FDA has granted 510(k) clearance to Prolift Pivot expandable spacer system, expanding Life Spine’s Micro Invasive tech portfolio The system provides full articulation for precise spinal fusion, while reducing tissue disruption & nerve retraction, allowing surgeons to restore patient alignment with superior control & efficiency. It also features OSSEO-LOC surface tech that promotes osseointegration & long-term…
January 30, 2025
Pet Honesty Introduces Urinary Tract Health for Cats
Shots: Pet Honesty launched Urinary Tract Health, a supplement to promote cats' urinary health, expanding its feline wellness product portfolio Urinary Tract Health chews contain cranberry, glucosamine, & probiotics to support normal urinary function, gut health & maintain urine pH This is a dual-texture cat supplement to increase palatability in cats, plus provide…
January 29, 2025
Lantheus Holdings to Acquire Evergreen Theragnostics for ~$1B
Shots: Lantheus will acquire Evergreen Theragnostics for $250M upfront plus ~$752.5M development & sales milestones related to Octevy & other assets in an all-cash transaction, with closing anticipated in H2’25 pending regulatory approvals The acquisition will add Evergreen’s Octevy (registrational-stage PET imaging agent for somatostatin receptor +ve NETs in adults & pediatrics) complementing Lantheus'…
January 29, 2025
Zimmer Biomet to Acquire Paragon 28 for ~$1.2B
Shots: Zimmer Biomet has agreed to acquire Paragon 28 for $13.00/share in cash with an equity value of ~$1.1B & enterprise value of ~$1.2B. Closing is expected in H1’25 As per the terms, shareholders will also get a non-tradeable CVR of $1/share on achieving revenue milestones, which is payable from $0 to $1 (calculated linearly)…
January 29, 2025
ITM
ITM Reports Topline Data from P-III (COMPETE) Trial of ITM-11 to Treat Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Shots: The P-III (COMPETE) trial assessed ITM-11 (7.5 GBq + nephroprotective amino acid, Q3M × max. 4 cycles) vs everolimus (10mg for ~30mos. or until disease progression) in patients (n=309) with inoperable, progressive, SSTR+ gr 1/2 GEP-NETs. The US FDA’s NDA submission is expected in 2025 The study met its 1EP of improved PFS,…
January 29, 2025
Load more